Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others

Abstract

Global discussions are ongoing on how to stimulate antibiotic research and development in order to provide patients with new antibiotics able to address the challenges of antimicrobial resistance. In this supplement, we present nine articles derived from the research performed as part of the Innovative Medicine Initiative-funded DRIVE-AB project and others. These publications provide new evidence and arguments in the debate around economic incentives to stimulate antibiotic innovation, including characteristics, implementation and governance.

Get full access to this article

View all access options for this article.

References

Tacconelli ,

Carrara ,

Savoldi ,

Harbarth ,

Mendel-son ,

D. L.

Monnet ,

Pulcini ,

Kahlmeter ,

Kluytmans ,

Carmeli ,

Ouellette ,

Outterson ,

Patel ,

Cavaleri ,

E. M.

Cox ,

C. R.

Houchens ,

M. L.

Grayson ,

Hansen ,

Singh ,

Theuretzbacher, and

Magrini , WHO Pathogens Priority List Working Group, “Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis,” The Lancet Infectious Diseases 18, no. 3 (2018): 318-327.

G20 Germany 2017, Berlin Declaration of the G20 Health Ministers, available at <https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/G/G20-Gesundheitsministertreffen/G20_Health_Ministers_Declaration_engl.pdf> (last visited February 11, 2018).

L. L.

Silver

, “Challenges of Antibacterial Discovery,” Clinical Microbiology Reviews 24, no. 1 (2011): 71-109; J. F. Tomayko, J. H. Rex, D.M. Tenero, M. Goldberger, and B. I. Eisenstein, “The Challenge of Antimicrobial Resistance: New Regulatory Tools to Support Product Development,” Clinical Pharmacology & Therapeutics 96, no. 2 (2014): 166-168; S. Harbarth, U. Theuretzbacher, J. Hackett, and the DRIVE-AB Consortium, “Antibiotic Research and Development: Business as Usual?” Journal of Antimicrobial Chemotherapy 70, no. 6 (2015): 1604-1607.

Innovative Medicine Initiative (IMI), available at <www.imi.europa.eu> (last visited February 7, 2018);

Kostyanev ,

deWinter ,

Steel ,

Ross ,

O'Brien ,

François ,

Winterhalter ,

Stavenger ,

Karlén ,

Harbarth ,

Hackett ,

Jafri ,

Vuong ,

Mac Gowan ,

Witschi ,

Angyalosi ,

Elborn ,

Bonten , and

Goossens for the ND4BB Consortia, “The Innovative Medicines Initiative's New Drugs for Bad Bugs Programme – European Public-Private Partnerships for the Development of New Strategies to Tackle Antibiotic Resistance,” Journal of Antimicrobial Chemotherapy 71 (2016): 290-295.

DRIVE-AB Final Report, “Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access,” 2018, available at <http://www.imi.europa.eu/projects-results/project-factsheets/drive-ab> (last visited February 7, 2018).

Id.

Savic and

Årdal , “A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 9-24

Baraldi ,

Lindahl ,

Savic ,

Findlay , and

Årdal , “Antibiotic Pipeline Coordinators,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 25-31.

See DRIVE-AB Final Report, supra note 5.

10.

Okhravi ,

Callegari ,

McKeever ,

Kronlid ,

Baraldi ,

Lindahl , and

Ciabuschi , “Simulating Market Entry Rewards for Antibiotics Development,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 32-42.

11.

Årdal ,

Johnsen , and

Johansen , “Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 43-49.

12.

G. W.

Daniel ,

Schneider ,

M. Hamilton

Lopez , and

M. B.

McClellan , “Implementation of a Market Entry Reward within the United States,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 50-58.

13.

G. W.

Daniel ,

Schneider , and

M. B.

McClellan , “Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award,” JAMA 318, no. 2 (2017): 1103-1104.

14.

Bhatti ,

Lum ,

Holland ,

Sassman ,

Findlay , and

Outterson , “A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 59-65.

15.

Lum ,

Bhatti ,

Holland ,

Guthrie , and

Sassman , “Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 66-74.

16.

See DRIVE-AB Final Report, supra note 5, at 15.

17.

Id., at 53-57.

18.

C. M.

Morel and

S. E.

Edwards , “Encouraging Sustainable Use of Antibiotics within the DRIVE AB Selected Innovation Incentives,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 75-80.

19.

Storehagen ,

Aftab ,

Årdal ,

Savic , and

J. A.

Røttingen , “Should Antibiotics Be Controlled Medicines? Lessons from the Controlled Drug Regimen,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 81-94.

20.

Årdal ,

Outterson ,

S. J.

Hoffman ,

Ghafur ,

Sharland ,

Ranganathan ,

Smith ,

Zorzet ,

Cohn ,

Pittet ,

Daulaire ,

Morel ,

Rizvi ,

Balasegaram ,

O. A.

Dar ,

D. L.

Heymann ,

A. H.

Holmes ,

L. S.

Moore ,

Laxminarayan ,

Mendelson , and

J. A.

Røttingen , “International Cooperation to Improve Access to and Sustain Effectiveness of Antimicrobials,” The Lancet 387, no. 10015 (2016): 296-307.

21.

World Health Organization (WHO), “Global Action Plan on Antimicrobial Resistance,” 2015, available at <http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/> (last visited February 7, 2018).